Athira Preclinical Data Highlights Fosgonimeton Treatment in Models of Alzheimer’s

 Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease

 Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease. The original research article, “Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics. Fosgonimeton is a potentially first-in-class, once daily, subcutaneously administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system, and is in development for neurodegenerative disorders, including Alzheimer’s disease.

https://www.biospace.com/article/releases/athira-pharma-announces-publication-of-preclinical-data-highlighting-fosgonimeton-treatment-in-models-of-alzheimer-s-disease/